Institutional members access full text with Ovid®

Share this article on:

Successful Treatment of Recurrent Pediatric Inflammatory Myofibroblastic Tumor in a Single Patient With a Novel Chemotherapeutic Regimen Containing Celecoxib

Johnson, Kevin MD*; Notrica, David M. MD*,†,‡; Carpentieri, David MD§,∥,¶; Jaroszewski, Dawn MD#; Henry, Michael M. MD**

Journal of Pediatric Hematology/Oncology: July 2013 - Volume 35 - Issue 5 - p 414–416
doi: 10.1097/MPH.0b013e3182915cef
Clinical and Laboratory Observations

Inflammatory myofibroblastic tumors are rare tumors characterized as low-to-intermediate grade sarcomas. This is a case of a 7-year-old male with a 5-cm lung mass, which recurred 11 months after complete resection. The recurrence manifested as multifocal metastatic disease involving the ipsilateral parietal and visceral pleura. A novel chemotherapeutic regimen, which included vincristine, ifosfamide, doxorubicin, and celecoxib was utilized for the disease recurrence. The patient had complete and durable remission of the disease and has been disease-free for >4 years. This novel regimen including a cyclooxygenase 2 inhibitor may be an effective regimen for metastatic inflammatory myofibroblastic tumors.

*Department of General Surgery, Mayo Clinic

Department of Child Health, University of Arizona College of Medicine Phoenix

Department of Surgery, University of Arizona College of Medicine

Departments of §Pediatrics and Clinical Pathology

**Center for Cancer and Blood Disorders, Phoenix Children's Hospital

Phoenix Children’s Hospital

#Department of Surgery, Division of Thoracic Surgery, Mayo Clinic, Phoenix, AZ

Department of Pathology, Mayo Medical School, Rochester, MN

The authors declare no conflict of interest.

Reprints: Michael M. Henry, MD, Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ 85016 (e-mail:

Received December 19, 2011

Accepted March 10, 2013

© 2013 by Lippincott Williams & Wilkins.